Expiration Date: July 14, 2017
By clicking "Continue to Activity" you attest that you have read and understood the CME required elements. Continue to Activity
Estimated Time to Complete45 minutes
Activity OverviewHuntington disease (HD) is a rare neurodegenerative disorder of the central nervous system (CNS) characterized by abnormal involuntary movements, behavioral disturbance, cognitive dysfunction, and psychiatric disease. Currently, there is no established treatment to delay the onset or prevent the progression of HD, and available pharmacologic interventions for controlling the motor and non-motor aspects of the disease are limited. However, recent therapeutic advances, particularly in suppressing chorea, have been shown to have a favorable effect on motor function, safety, and quality of life. In this roundtable discussion, recorded immediately after the 2016 International Congress of Parkinson's Disease and Movement Disorders Meeting in Berlin, Germany, leading experts in HD explore some of the most recent evidence and latest developments in the treatment for this devastating disease.
ProvidershipThis continuing medical education activity is provided
Support AcknowledgementThis activity is supported by an educational grant from Teva Pharmaceuticals.
Learning ObjectivesUpon successful completion of the activity, participants should be better able to:
- Review the latest data of the use of predictive testing and biomarkers in patients who are carriers of the mutant Htt gene variant prior to conversion to manifest HD.
- Evaluate the latest clinical data regarding the mechanism of action, efficacy, and safety of available and emerging agents for the management of chorea and other symptoms associated with HD.
- Assess the utilization of emerging agents in the management of patients with HD.